Rowan Dunne
Rowan Dunne is a niche, counterculture-leaning business reporter at Mugglehead who covers emerging health technologies and other specialized sectors through the lens of the stock market. His reporting centres on how scientific advances, medical devices and wellness products translate into investor momentum and corporate milestones. He has filed more than 2,500 stories for the masthead over more than four years, giving him a deep track record of fast-moving coverage in health, medtech and adjacent industries.
Cancer screening and therapeutic innovation
Dunne’s health coverage is anchored in detailed reporting on cancer screening methods and experimental therapeutics, with a strong emphasis on both clinical results and market reaction. In his piece on liquid chromatography-mass spectrometry in lung cancer screening, he explains how metabolite profiling from simple blood draws can detect early-stage disease with high accuracy, breaking out performance metrics and practical details such as sample volume and assay speed.
He highlights the way LC-MS can be applied to blood and breath samples and connects those technical strengths to potential adoption in jurisdictions facing rising lung cancer rates. Headlines on bioAffinity Technologies’ Hong Kong lung cancer screening patent and Longeveron’s stem cell therapy study failure show him tracking how regulatory milestones and trial setbacks move share prices, often quantified in large percentage swings. A report on Propanc Biopharma’s pancreatic cancer drug work describes tumour growth reductions of more than 90 per cent in animal models and links that data to a stock move of over 150 per cent, underscoring his habit of pairing experimental results with immediate market impact.
He also covers psychedelic drug development, including a major therapeutics and drug development conference, indicating a sustained interest in frontier treatment modalities that sit close to investor sentiment and regulatory scrutiny.
Small-cap health and medtech stocks
Dunne regularly focuses on small-cap and micro-cap health companies where single announcements can drive extreme volatility. His coverage of CNS Pharma’s 250 per cent share price spike following an oversubscribed private placement breaks down financing dynamics and investor appetite rather than treating the move as an isolated anomaly.
Stories on oncology and biotech names such as Propanc Biopharma show the same pattern: he identifies the scientific catalyst, quantifies the stock reaction and situates both in a broader narrative about early-stage companies fighting for capital and attention. Beyond pure therapeutics, he follows medtech and wellness firms that blend clinical claims with consumer appeal, often flagging the competitive edge or differentiating feature that might matter to investors.
This small-cap focus makes his health beat particularly relevant to companies whose news flow directly drives valuations, whether through trial readouts, patents or funding events.
Sleep technology and brain health devices
Sleep technology and brain-focused wearables are a recurring thread in Dunne’s reporting, reflecting his interest in health products that sit between clinical practice and everyday life.
In his coverage of NextSense’s brain-sensing EEG Smartbuds, he describes how wireless earbuds integrate multiple clinical-grade EEG sensors to monitor brain activity in real time, and he explains how the device supports neuromodulation and brain health tracking for consumers. He notes platform requirements and technical constraints, showing attention to practical adoption details rather than only promotional claims. A story on Coway’s sleep tech mattress links product engineering to a “goofy” animated marketing campaign, signalling his awareness that branding and user experience can be as important as hardware specifications in this niche.
Across these pieces he treats sleep and brain health as investable themes, giving equal weight to design, scientific grounding and the commercial strategies behind new devices.
Mining, regulation and cross-sector coverage
Although health is a major focus, Dunne’s beat also spans mining, industrial safety and technology-adjacent sectors, unified by a capital markets viewpoint. He has reported on Polish mining major KGHM receiving multiple safety accolades in Nevada, drawing out operational performance and safety culture as material factors for a large producer.
Coverage of European regulators objecting to MMG’s proposed Anglo American nickel takeover shows him following competition concerns and regulatory pushback in detail, treating policy decisions as critical inputs for deal-making and commodity investors. Earlier work references joint ventures with sub-par performance and other mining stories, reinforcing his comfort with production metrics and corporate structures alongside health and tech topics.
He also writes about AI and education technology, such as KIDZ AI’s surge after an award win, and emerging tech names in robotics and sleep technology, keeping a consistent focus on how niche and counterculture-leaning businesses turn innovation into market movement. Taken together, this cross-sector portfolio positions him as a reporter who connects specialized subject matter to its financial and regulatory stakes rather than treating it as standalone science or industry news.
4 more health journalists.
Alanna Smith
Alanna Smith is a national health reporter whose work links health policy and politics to real access to care, with a constant focus on health equity, infectious disease and the toxic drug crisis. She reports for The Globe and Mail on infectious diseases, hospitals and long-term care, mental health, drug policy and the pressures on health systems in Western Canada. Her stories connect big-picture decisions to patients, families, front-line workers and volunteers, showing how funding, privatization and federal standards shape public care. She has covered trauma care inequities, proposed public‑private models in Alberta, drug toxicity and overdose policy, respiratory virus surges, measles elimination, gene‑editing advances and gender‑affirming health care laws. Her work combines narrative reporting, data, legal and policy analysis, and has been recognized by national journalism and press freedom organizations.
Allan Levine
Allan Levine is a historian and author whose journalism uses the past to explain present-day issues. He writes for the Winnipeg Free Press, including the Now & Then column, which examines current events through history. His subjects include public health, disease, medical treatment, health systems, politics, social conflict, strikes, wars, antisemitism and Canadian public life. His polio reporting traces Manitoba epidemics, hospital pressures, treatment, mortality and the arrival of vaccines through archival data and medical history. He also writes about the Winnipeg General Strike and Jewish communities, including discrimination, rights and security. His work draws on books about Canadian political leaders, Jewish history and the wartime economy, including The Dollar A Year Men. He writes long-form, analytical pieces that combine dates, statistics, policy decisions and narrative storytelling to connect people and institutions with broader historical change.
Angela Amato
Angela Amato is a digital news producer with CTV News, and her coverage is distinct for linking health research and public safety concerns to legal and policy decisions that shape daily life. She reports on health, justice, politics, business, arts and culture, crime and public-interest stories. Her health work covers academic and clinical research, including studies on vaping and lung blood flow, exercise tolerance and early heart dysfunction in young adults. She also reports on motorcycle gang arrests, homicide and death investigations, Indigenous justice stories, wildfire evacuations, ambulance contracts, property taxes, labour negotiations and political advocacy rules. She explains complex findings in plain language and stays close to documents, data and expert sources. Her background includes investigative and daily newsrooms, and she has earned nominations for national journalism awards.
Apoorva Mandavilli
Apoorva Mandavilli covers the collision of infectious disease science, vaccine policy and public health agencies for The New York Times, following how research, regulation and politics shape outbreaks and access to vaccines. She reports on science and global health with a steady focus on infectious diseases and pandemics, including Covid-19, mpox, H.I.V., malaria and tuberculosis, treating them as ongoing global threats. Her work explains complex epidemiology and virology in clear narratives about risk, evidence and the consequences of scientific decisions. She repeatedly returns to vaccine policy, law and misinformation, tracing how court fights and agency disputes affect immunization schedules and public trust. She also reports on global health programs, funding cuts and inequity in care and technology. A longtime science journalist and former founding editor in chief of Spectrum, she has written widely on science and health and received major honors for medical science reporting and pandemic coverage.